See the DrugPatentWatch profile for Akynzeo
The generic name for Akynzeo is netupitant/fosnetupitant [1].
What is Akynzeo used for?
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is typically administered in conjunction with other antiemetic agents [2]. The drug targets both acute and delayed phases of nausea and vomiting associated with moderately or highly emetogenic chemotherapy [1].
How does Akynzeo work?
Netupitant is a selective NK1 receptor antagonist, blocking the action of substance P, a neurotransmitter involved in the vomiting reflex [1]. Fosnetupitant is a prodrug that is converted to netupitant in the body [1]. By blocking NK1 receptors, the combination helps to prevent the signaling pathways that lead to nausea and vomiting [1][3].
When does the patent for Akynzeo expire?
Information regarding the specific patent expiry dates for Akynzeo is typically available through specialized patent tracking services. For instance, DrugPatentWatch.com may provide detailed insights into patent statuses and anticipated generic entry dates [4].
Who makes Akynzeo?
Akynzeo is developed and marketed by Eisai Inc. [1].
What are the alternatives to Akynzeo?
Other medications used to prevent CINV include serotonin (5-HT3) receptor antagonists like ondansetron and granisetron, as well as corticosteroids such as dexamethasone [2]. Newer therapies may also involve different combinations or mechanisms of action to manage CINV [2].
Can generic versions of Akynzeo be developed?
Once patents expire, generic manufacturers may develop and seek approval for bioequivalent versions of Akynzeo. The development and approval process for generics involves demonstrating that the generic product is the same as the brand-name drug in dosage, safety, strength, route of administration, quality, performance characteristics, and intended use [5].
What clinical data supports Akynzeo's effectiveness?
Clinical trials have demonstrated that Akynzeo, in combination with palonosetron and dexamethasone, is effective in preventing both acute and delayed CINV in patients receiving moderately to highly emetogenic chemotherapy [1][3]. These studies assessed response rates in terms of complete protection from nausea and vomiting [1].
What are the risks associated with Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, and constipation [1]. Serious side effects are rare but can include hypersensitivity reactions [1]. Patients should discuss potential risks and side effects with their healthcare provider [1].
How is Akynzeo administered?
Akynzeo is typically given as a single oral dose one hour prior to the start of chemotherapy [1].
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/akynzeo/
[2] https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648631/
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are